

Supporting information for

**The Discovery of AM-6494: A Potent and Orally Efficacious  $\beta$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with *in vivo* Selectivity over BACE2**

Liping H. Pettus,\*<sup>1</sup> Matthew P. Bourbeau,<sup>1</sup> Jodi Bradley,<sup>2</sup> Michael D. Bartberger,<sup>3</sup> Kui Chen,<sup>4</sup> Dean Hickman,<sup>5</sup> Michael Johnson,<sup>6</sup> Qingyian Liu,<sup>1</sup> James R. Manning,<sup>1</sup> Adrian Nanez,<sup>7</sup> Aaron C. Siegmund,<sup>1</sup> Paul H. Wen,<sup>2</sup> Douglas A. Whittington,<sup>3</sup> Jennifer R. Allen,<sup>1</sup> and Stephen Wood<sup>2</sup>


<sup>1</sup>Medicinal Chemistry, <sup>2</sup>Neuroscience Research, <sup>3</sup>Molecular Engineering, <sup>4</sup>Discovery Technologies, <sup>5</sup>Pharmacokinetics and Drug Metabolism, <sup>6</sup>Research Automation and Technologies, <sup>7</sup>Comparative Biology and Safety Studies, Amgen Discovery Research, Thousand Oaks, CA 91320

Table of Contents

Table SI-1. Cross species biochemical IC <sub>50</sub> data for compounds <b>20</b> and <b>25</b>	S2
Figure SI-1. Dose response curves of <b>1</b> , <b>20</b> , and <b>25</b> tested in BACE2 cell-based assay	S2
Experimental procedure for <b>20</b> (AM-6494) in complex with BACE1 (PDB 6PZ4)	S3

**Table SI-1.** Cross species biochemical IC<sub>50</sub> data for compounds **20** and **25**

Compd	human BACE1 IC <sub>50</sub> (μM)	rat BACE1 IC <sub>50</sub> (μM)	mouse BACE1 IC <sub>50</sub> (μM)	dog BACE1 IC <sub>50</sub> (μM)	monkey BACE1 IC <sub>50</sub> (μM)
<b>20</b>	4.3271E-4 +/- 1.77E-4 (n=17)	6.1775E-4 +/- 5.25E-4 (n=4)	3.5975E-4 +/- 8.54E-5 (n=4)	4.205E-4 +/- 4.66E-5 (n=4)	3.4658E-4 +/- 1.11E-4 (n=4)
<b>25</b>	2.0722E-4 +/- 8.28E-5 (n=18)	3.0675E-4 +/- 1.72E-4 (n=4)	1.9525E-4 +/- 1.0E-4 (n=4)	1.73E-4 +/- 7.37E-5 (n=4)	1.5737E-4 +/- 5.16E-5 (n=4)



**Figure SI-1.** Dose response curves of **1**, **20**, and **25** tested in BACE2 cell-based (HEK293 cells) assay plotted as percent of control (POC). IC<sub>50</sub> values are 53.4, 484.5, and 1240 nM for **1**, **20**, and **25**, respectively.

### Experimental procedure for **20** (AM-6494) in complex with BACE1 (PDB 6PZ4)

The extracellular domain of BACE1 was expressed, purified, and crystallized according to published procedures.<sup>1</sup> Inhibitor-bound BACE1 crystals were prepared by soaking apo crystals in a mother liquor solution supplemented with 1 mM of compound **20** (AM-6494) for 5 h at room temperature. Crystals were transferred briefly into a cryo solution consisting of 25% (w/v) PEG 5000 MME, 0.1 M sodium citrate (pH 6.6), 0.2 M ammonium iodide, and 20% (v/v) glycerol prior to being flash frozen in liquid nitrogen. Diffraction data were collected on the APS SER-CAT 22-BM equipped with a Mar 225 detector. Images were processed using the HKL suite of programs.<sup>2</sup> The structures were refined using REFMAC,<sup>3</sup> and model building was performed with COOT.<sup>4</sup>

### References

- (1) Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C.M.; Yon, J. Apo and inhibitor complex structures of BACE ( $\beta$ -secretase) *J. Mol. Biol.* **2004**, *343*, 407-416.
- (2) Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* **1997**, *276*, 307-326.
- (3) Murshudov, G.N.; Vagin, A.A.; Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr.* **1997**, *D53*, 240-255.
- (4) Emsley, P.; Cowtan, K. *Coot*: model-building tools for molecular graphics. *Acta Crystallogr.* **2004**, *D60*, 2126-2132.